Uae Cell And Gene Therapy Manufacturing Market Size & Outlook
The cell and gene therapy manufacturing market in the UAE is expected to reach a projected revenue of US$ 82.0 million by 2030. A compound annual growth rate of 15.2% is expected of the UAE cell and gene therapy manufacturing market from 2023 to 2030.
UAE cell and gene therapy manufacturing market highlights
The UAE cell and gene therapy manufacturing market generated a revenue of USD 26.4 million in 2022 and is expected to reach USD 82.0 million by 2030.
The UAE market is expected to grow at a CAGR of 15.2% from 2023 to 2030.
In terms of segment, cell therapy was the largest revenue generating therapy type in 2022.
Gene Therapy is the most lucrative therapy type segment registering the fastest growth during the forecast period.
Cell and gene therapy manufacturing market data book summary
Market revenue in 2022
USD 26.4 million
Market revenue in 2030
USD 82.0 million
Growth rate
15.2% (CAGR from 2023 to 2030)
Largest segment
Cell therapy
Fastest growing segment
Gene Therapy
Historical data
2018 - 2021
Base year
2022
Forecast period
2023 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Gene Therapy, Cell Therapy
Key market players worldwide
Lonza Group Ltd, Bluebird bio Inc, Catalent Inc, Roche, Samsung BioLogics, Boehringer Ingelheim, Hitachi Ltd, Takara Bio Inc, Miltenyi Biotec, Thermo Fisher Scientific Inc, Novartis AG ADR, Merck KGaA, Wuxi AppTec Co Ltd
Other key industry trends
In terms of revenue, UAE accounted for 0.4% of the global cell and gene therapy manufacturing market in 2022.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Middle East & Africa, South Africa cell and gene therapy manufacturing market is projected to lead the regional market in terms of revenue in 2030.
South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 180.3 million by 2030.
Stem cell therapy is gaining popularity in the UAE. The development of the regenerative medicine industry is aided by certain trends in the UAE's healthcare sector. UAE is moving away from importing medicines & healthcare products and instead allocating funds to support local production of therapeutic & pharmaceutical goods.
Furthermore, the expansion of regenerative medicine in the country is fueled by cutting-edge biotherapies such as immunomodulation therapy, gene & cell therapies, and tissue engineering. For instance, in August 2020, Abu Dhabi Stem Cells Center collaborated with Pluristem Therapeutics, Inc. to develop regenerative medicine and cell therapies to treat severe diseases, including COVID-19.
Moreover, according to an article published in Khaleej Times, in November 2022, gene therapy was used to treat a child suffering from a rare genetic disorder. Dubai is becoming the destination of choice in the Middle East region for the treatment of genetic conditions through gene therapy. For instance, in October 2021, UAE-Novartis, involved in advancing cell and gene therapy, has been able to help patients facing the threat of developing blindness.
UAE Cell And Gene Therapy Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Cell And Gene Therapy Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Cell Therapy was the largest segment with a revenue share of 67.05% in 2022.
Horizon Databook has segmented the Uae cell and gene therapy manufacturing market based on gene therapy, cell therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Stem cell therapy is gaining popularity in the UAE. The development of the regenerative medicine industry is aided by certain trends in the UAE's healthcare sector. UAE is moving away from importing medicines & healthcare products and instead allocating funds to support local production of therapeutic & pharmaceutical goods.
Furthermore, the expansion of regenerative medicine in the country is fueled by cutting-edge biotherapies such as immunomodulation therapy, gene & cell therapies, and tissue engineering. For instance, in August 2020, Abu Dhabi Stem Cells Center collaborated with Pluristem Therapeutics, Inc. to develop regenerative medicine and cell therapies to treat severe diseases, including COVID-19.
Moreover, according to an article published in Khaleej Times, in November 2022, gene therapy was used to treat a child suffering from a rare genetic disorder. Dubai is becoming the destination of choice in the Middle East region for the treatment of genetic conditions through gene therapy. For instance, in October 2021, UAE-Novartis, involved in advancing cell and gene therapy, has been able to help patients facing the threat of developing blindness.
Uae Cell And Gene Therapy Manufacturing Market Therapy Type Outlook (Revenue, USD Million , 2018-2030)
Gene Therapy
Cell Therapy
Uae Cell And Gene Therapy Manufacturing Market Scale Outlook (Revenue, USD Million , 2018-2030)
Pre-commercial/ R&D Scale
Commercial Scale
Uae Cell And Gene Therapy Manufacturing Market Mode Outlook (Revenue, USD Million , 2018-2030)
Contract manufacturing
In house manufacturing
Uae Cell And Gene Therapy Manufacturing Market Workflow Outlook (Revenue, USD Million , 2018-2030)
Cell Processing
Cell Banking
Process Development
Fill & Finish Operations
Analytical & Quality Testing
Raw Material Testing
Vector Production
Others
Uae Cell And Gene Therapy Manufacturing Market Indication Outlook (Revenue, USD Million , 2018-2030)
Acute Lymphoblastic Leukemia (ALL)
Inherited Retinal Disease
Malignancies
Musculoskeletal therapies
Autoimmune disorders
Dermatology
Large B-Cell Lymphoma
Spinal Muscular Atrophy (SMA)
Others
Reasons to subscribe to Cell And Gene Therapy Manufacturing Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Cell And Gene Therapy Manufacturing Market Outlook databook
Our clientele includes a mix of Cell And Gene Therapy Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE Cell And Gene Therapy Manufacturing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into UAE Cell And Gene Therapy Manufacturing Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Uae Cell And Gene Therapy Manufacturing Market, 2018-2030 (US$M)